Xvivo Perfusion announced during the morning that an XPS has been installed at the Shanghai Pulmonary Hostpital. An investigator initiated clinical trial will now begin, which will complement existing data and take the company towards market approval. China is a rapidly growing market with high potential, but broad market uptake will likely take time and the news do not result in any changes in our valuation of the company.